Skip to main content
. 2012 May;180(5):2018–2027. doi: 10.1016/j.ajpath.2012.01.028

Figure 5.

Figure 5

RvD1 stimulates specific proresolving miRNAs in hALX/FPR2 transgenic (Tg) mice. miRNA fractions were isolated from peritonitis exudate samples of WT littermates and ALX/FPR2-Tg mice challenged with zymosan (1 mg per mouse) compared with mice given RvD1 (10 ng per mouse with zymosan). Real-time PCR analyses of indicated miRNAs were performed and results were analyzed by the 2−ΔCT method. Fold change in expression levels in RvD1-treated mice compared with zymosan alone were calculated from 2−ΔCT values. Results are expressed as mean ± SEM (n = 3 in each group) fold change in levels of miR-208a (A), miR-219 (B), and miR-21, miR-146b, and miR-302d (C). *P < 0.05 for RvD1-treated versus zymosan-treated WT or Tg mice; †P < 0.05 for zymosan + RvD1–treated Tg mice versus zymosan + RvD1–treated WT mice. D: miR-208a and miR-219 expression levels determined by real-time PCR in peritoneal cells from untreated mice.